These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 24585360)

  • 1. Strategies to overcome the barrier: use of nanoparticles as carriers and modulators of barrier properties.
    Rempe R; Cramer S; Qiao R; Galla HJ
    Cell Tissue Res; 2014 Mar; 355(3):717-26. PubMed ID: 24585360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming the blood-brain barrier in neurodegenerative disorders and brain tumours.
    Ebrahimi Z; Talaei S; Aghamiri S; Goradel NH; Jafarpour A; Negahdari B
    IET Nanobiotechnol; 2020 Aug; 14(6):441-448. PubMed ID: 32755952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Magnetic Nanoparticles Cross the Blood-Brain Barrier: When Physics Rises to a Challenge.
    Busquets MA; Espargaró A; Sabaté R; Estelrich J
    Nanomaterials (Basel); 2015 Dec; 5(4):2231-2248. PubMed ID: 28347118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood-Nanoparticle Interactions Create a Brain Delivery Superhighway for Doxorubicin.
    Li Z; Kovshova T; Malinovskaya J; Knoll J; Shanehsazzadeh S; Osipova N; Chernysheva A; Melnikov P; Gelperina S; Wacker MG
    Int J Nanomedicine; 2024; 19():2039-2056. PubMed ID: 38476274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery.
    Ronaldson PT; Davis TP
    Ther Deliv; 2011 Aug; 2(8):1015-41. PubMed ID: 22468221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Advances in Delivery of Peptide and Protein Therapeutics to the Brain.
    Arora S; Bajaj T; Kumar J; Goyal M; Singh A; Singh C
    J Pharmacol Exp Ther; 2024 Jan; 388(1):54-66. PubMed ID: 37977811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood-Brain Barrier-Targeting Nanoparticles: Biomaterial Properties and Biomedical Applications in Translational Neuroscience.
    Asimakidou E; Tan JKS; Zeng J; Lo CH
    Pharmaceuticals (Basel); 2024 May; 17(5):. PubMed ID: 38794182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurological disorders and therapeutics targeted to surmount the blood-brain barrier.
    Kanwar JR; Sriramoju B; Kanwar RK
    Int J Nanomedicine; 2012; 7():3259-78. PubMed ID: 22848160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Reevaluation of Chitosan-Decorated Nanoparticles to Cross the Blood-Brain Barrier.
    Cortés H; Alcalá-Alcalá S; Caballero-Florán IH; Bernal-Chávez SA; Ávalos-Fuentes A; González-Torres M; González-Del Carmen M; Figueroa-González G; Reyes-Hernández OD; Floran B; Del Prado-Audelo ML; Leyva-Gómez G
    Membranes (Basel); 2020 Aug; 10(9):. PubMed ID: 32872576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of environmental nanoparticles on neurodegeneration.
    Hermosillo-Abundis C; Méndez-Rojas MA; Arias-Carrión O
    J Neurosci Res; 2024 May; 102(5):e25340. PubMed ID: 38745527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoprobe for blood-brain barrier changes.
    Kiani L
    Nat Rev Neurol; 2024 Jun; 20(6):316. PubMed ID: 38744999
    [No Abstract]   [Full Text] [Related]  

  • 12. Nanoparticles and blood-brain barrier: the key to central nervous system diseases.
    Domínguez A; Suárez-Merino B; Goñi-de-Cerio F
    J Nanosci Nanotechnol; 2014 Jan; 14(1):766-79. PubMed ID: 24730296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoparticle enabled drug delivery across the blood brain barrier: in vivo and in vitro models, opportunities and challenges.
    Gidwani M; Singh AV
    Curr Pharm Biotechnol; 2014; 14(14):1201-12. PubMed ID: 24809717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The blood-brain barrier: structure, function and therapeutic approaches to cross it.
    Tajes M; Ramos-Fernández E; Weng-Jiang X; Bosch-Morató M; Guivernau B; Eraso-Pichot A; Salvador B; Fernàndez-Busquets X; Roquer J; Muñoz FJ
    Mol Membr Biol; 2014 Aug; 31(5):152-67. PubMed ID: 25046533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in delivery through the blood-brain barrier.
    Larsen JM; Martin DR; Byrne ME
    Curr Top Med Chem; 2014; 14(9):1148-60. PubMed ID: 24678707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting delivery of etoposide to inhibit the growth of human glioblastoma multiforme using lactoferrin- and folic acid-grafted poly(lactide-co-glycolide) nanoparticles.
    Kuo YC; Chen YC
    Int J Pharm; 2015 Feb; 479(1):138-49. PubMed ID: 25560309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lactoferrin- and antitransferrin-modified liposomes for brain targeting of the NK3 receptor agonist senktide: preparation and in vivo evaluation.
    De Luca MA; Lai F; Corrias F; Caboni P; Bimpisidis Z; Maccioni E; Fadda AM; Di Chiara G
    Int J Pharm; 2015 Feb; 479(1):129-37. PubMed ID: 25560308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donepezil-Loaded Nanocarriers for the Treatment of Alzheimer's Disease: Superior Efficacy of Extracellular Vesicles Over Polymeric Nanoparticles.
    Oliveira Silva R; Counil H; Rabanel JM; Haddad M; Zaouter C; Ben Khedher MR; Patten SA; Ramassamy C
    Int J Nanomedicine; 2024; 19():1077-1096. PubMed ID: 38317848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Commentary: Nanoparticle-Based Chemotherapy Delivery and Potential Health Risks: Prospects for Effective Clinical Translation.
    Assefa D; Melaku T; Alemu S
    Technol Cancer Res Treat; 2023; 22():15330338231220171. PubMed ID: 38130152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic Effects of Natural Products on Cervical Cancer: Based on Inflammatory Pathways.
    Zhou ZW; Long HZ; Xu SG; Li FJ; Cheng Y; Luo HY; Gao LC
    Front Pharmacol; 2022; 13():899208. PubMed ID: 35645817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.